ASCO GU 2017: Assessment of urologists experience with abiraterone acetate and with a real-world trial: Results obtained from a Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC). - Session Highlights
Based on survey results, the ease of use and success in integration of abiraterone into a urology practice was stated to be easy by half of the participants. Others said it was easy once they overcame few barriers (46.7%). 3.3% said it was a challening process due to certain identified barriers. The barrieres identified were time involvement and resource issues such as nursing support and lack of appropriate infrastructure. After participation in the COSMIC trial, 90% of the active sites indicated that treating with abiraterone will be part of their practice after the trial. This report indicates that integration of Abiraterone in urology practices is considered feasible for most urologists. There is interest in participating in future trials of this nature among urologists and such studies may help community and acedmic urologist overcome initial barriers. This supports the concept active participation in clinical trials improves ones practice patterns. Clinical trial information: NCT02364531
Author: Andrew Feifer
Written By: Michael J Metcalfe, MD, Fellow of Urologic Oncology Urology, MD Anderson Cancer Center, Houston TX
Ashish M. Kamat, MD, MBBS, FACS, President, International Bladder Cancer Network Chair, Society of Immunotherapy for Cancer (SITC), BCTF, Director of Urologic Oncology Fellowship, Professor of Urology, Attending Surgeon, Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston TX
at the 2017 Genitourinary Cancers Symposium - February 16 - 18, 2017 – Orlando, Florida USA